Anti-ErbB3 antibodies and uses thereof
US9827310B2 · kind B2 · utility
2Cited by
19References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 1, 2016 |
| Grant date | Nov 28, 2017 |
| Priority date | — |
| Expiry date | Feb 1, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2800/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides antibodies that bind to ErbB3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human ErbB3. In certain embodiments, the antibodies of the present invention block the interaction of ErbB3 with an ErbB3 ligand such as neuregulin 1. The antibodies of the invention are useful for the treatment of various cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.